The future of Alzheimer Diagnosis; the basis for therapy

Philip Scheltens

Professor of Cognitive Neurology and Director of the Alzheimer Center at Amsterdam University Medical Centers, Netherlands

In this plenary talk I will highlight the evolution from a purely pathological diagnosis of AD in early 1900 to a purely biomarker based framework in 2019. I will discuss the value of the ATN framework in predicting decline in normal people and how this will influence clinical trial design for the future. In addition I will discuss the used of blood based biomarkers in this field and how they will change the selection of individuals in trials. Finally I will give my personal view on the trail / pharma landscape in Ad and why there is still room for optimism and action.